The most common management of DADA2 after diagnosis is TNFa inhibition (TNFi). This treatment serves those with vasculitic forms of the disease best, improving most symptoms and significantly preventing strokes. TNFi is ineffective in those with severe bone marrow dysfunction or immunodeficiency. In these patients, hematopoietic stem cell transplant is considered and upon successful completion can be curative. However, the risks associated with this procedure preclude its use in most patients. Ongoing pre-clinical studies are researching gene therapy. Both gene therapy and enzyme replacement therapy have been successful in the adenosine<unk>  deficiency, indicating their potential future success in DADA2.
Adenosine deaminase 2 deficiency
Adenosine deaminase deficiency
Adenine phosphoribosyltransferase deficiency
Adenosine monophosphate deaminase deficiency type 1
Guanidinoacetate methyltransferase deficiency
Galactose-1-phosphate uridylyltransferase deficiency
Aminoacylase 1 deficiency
Methylenetetrahydrofolate reductase deficiency